PRQR - プロキュ―ア―ル・セラピュ―ティクス （ProQR Therapeutics N.V.）

A share of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at $3.70 per share on Friday, up from $3.37 day before. While ProQR Therapeutics N.V. has overperformed by 9.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -54.71%, with highs and lows ranging from $8.60 […]

ProQR Therapeutics N.V. (NASDAQ:PRQR) closed Friday at $2.71 per share, up from $2.70 a day earlier. While ProQR Therapeutics N.V. has overperformed by 0.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -66.95%, with highs and lows ranging from $8.60 to $0.53, whereas […]

In the last trading session, 5.55 million shares of the ProQR Therapeutics N.V. (NASDAQ:PRQR) were traded, and its beta was 0.48. Most recently the company’s share price was $2.71, and it changed around $0.01 or 0.37% from the last close, which brings the market valuation of the company to $192.90M. PRQR currently trades at a … ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Forecast: Bullish Signals Pointing To $5.00 In 2022 Read More »

https://www.investing.com/news/pro/proqr-therapeutics-nv-pt-raised-to-3-at-citi-432SI-2969634

Gainers: ORIC Pharmaceuticals (ORIC) +56%. ProQR Therapeutics (PRQR) +38%

ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 06/24/22, with the stock price down by -16.27% to the previous day’s close as strong demand from buyers drove the stock to $0.68. Actively observing the price movement in the last trading, the stock closed the session at $0.81, falling within a range of $0.68 … Analysts Predict A Surge In ProQR Therapeutics N.V. (NASDAQ: PRQR)? Read More »

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S. ProQR presentation

Within the last quarter, ProQR Therapeutics (NASDAQ: PRQR ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 In the last 3 months, 6 analysts have offered 12-month price targets for ProQR Therapeutics. The company has an average price target of $4.92 with a high of $8.00 and a low of $2.00. Below is a summary of how these 6 analysts rated ProQR Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the … Full story available on Benzinga.com

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today reported its financial and operating results for the first quarter ended March 31, 2022, and provided a business update.

The following slide deck was published by ProQR Therapeutics N.V.

The following slide deck was published by ProQR Therapeutics N.V.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enrapturing stocks: Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS 7.84%), ProQR Therapeutics N.V. (NASDAQ:PRQR -0.39%) appeared first on Stocks Equity .

ProQR Therapeutics N.V. (NASDAQ: PRQR ) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform. The Company will suspend the development of QR-1123 for autosomal dominant retinitis pigmentosa, QR-504a for Fuchs endothelial corneal dystrophy, and all other Inherited Retinal diseases (IRD)-related research activities. ProQR will implement restructuring initiatives, including a 30% workforce reduction and the departure of Chief Scientific Officer Naveed Shams, expected to be effective in Q2. ProQR … Full story available on Benzinga.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) with the stream of 3.15% also noticed, India Enservco Corporation (AMEX:ENSV) encountered a rapid change of 85.19% in the last hour of Monday’s trading session. ProQR … The post Glistering Stock: ProQR Therapeutics N.V. (NASDAQ:PRQR), Enservco Corporation (AMEX:ENSV) appeared first on Stocks Equity .

During the last session, ProQR Therapeutics N.V. (NASDAQ:PRQR)’s traded shares were 3.38 million, with the beta value of the company hitting 0.57. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday loss of -1.64% or -$0.02. The 52-week high for the PRQR share is $9.46, that puts it down … Is ProQR Therapeutics N.V. (NASDAQ: PRQR) Still A Loss Stock Despite Being Down -85.02% YTD? Read More »